Chimeric Therapeutics Limited (ASX: CHM) CEO and Managing Director Jennifer Chow discusses the company’s new agreement with Case Western Reserve University.
Chimeric Therapeutics is developing ground-breaking CAR T cell therapies for solid tumors based on research at the City of Hope Cancer Centre in Los Angeles. The technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor targeting component of the CAR to reprogram T cells and is currently undergoing Phase 1 clinical trials at City of Hope in glioblastoma.
